ABSTRACT
INTRODUCTION
Abnormalities of serum vitamin D levels have been linked to various adverse health outcomes, including respiratory illness and reduced lung function. 1 However, debate remains about the relevance of these associations particularly with respect to the role of a number of confounding factors. 1, 2 It is postulated that vitamin D may influence respiratory health through several mechanisms including immune modulation and effects on lung structure. 3 Animal studies suggest that in female mice vitamin D deficiency causes airway hyper-responsiveness, increased airway smooth muscle mass and reduced transforming growth factor-β expression in lungs and that in utero vitamin D deficiency increases airway smooth muscle, impairs lung function and increases airway inflammation. 4 These effects represent potential mechanisms or risk factors for many respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD) and respiratory infections.
A meta-analysis of human birth cohort studies has demonstrated that increased in utero exposure to vitamin D is inversely associated with the risk of asthma and wheeze during childhood. 5 Low levels of vitamin D have been associated with current asthma and wheeze, 6 reduced asthma control and reduced lung function, 2 and worse asthma outcomes in children. 7 Although the association between vitamin D levels and risk of asthma in adults is somewhat inconsistent, a recent meta-analysis of placebo-controlled vitamin D intervention trials reported a reduction in both the risk of severe asthma and healthcare use in children and adults receiving vitamin D. 8 COPD is a significant respiratory health burden and a number of studies have sought to determine a link between COPD and vitamin D. Two case-control studies have shown that whilst vitamin D insufficiency and deficiency are prevalent amongst patients with COPD, this does not appear to influence the rate of lung function decline in mild-to-moderate COPD or to be associated with mortality. 9, 10 The role of vitamin D in immune modulation and the response to pathogens suggests an important function in the immediate response to respiratory infections which may be mediated partly via antimicrobial peptide production. 2 Seasonal variations of viral infections and vitamin D levels support the immune modulation theory 11 and chronic respiratory conditions can be initiated, exacerbated and may progress as a consequence of respiratory infections. [12] [13] [14] The relationship between vitamin D level and lung health may be influenced by a number of confounding factors 1, 15 which must be considered in the analyses of vitamin D and respiratory symptoms or disease.
The aim of this cross-sectional study was to relate serum vitamin D levels to respiratory symptoms, disease and lung function, adjusting for potential confounders in a well-described representative adult Australian population.
METHODS

Population and study sample
A community-based cross-sectional survey of Caucasian adults born between 1946 and 1964 (baby boomers) resident in the Shire of Busselton in Western Australia was undertaken from May 2010 to December 2015. 16 The study has received ethics approval from the University of Western Australia Human Research Ethics Committee (Number RA/4/1/2203). All residents of the Shire registered on the Electoral Roll (enrolment to vote is compulsory in Australia) were invited to participate. Of the 8223 residents on the electoral list, 6763 (82%) were contactable and confirmed eligible, and of these 5107 (76%) participated in the study. After excluding one person with lung cancer and those with missing data on key variables (excluding spirometry), 5011 were left for analyses. A subset of 4212 also had spirometry data and 2669 had an overnight sleep study.
Health assessments
Respiratory symptoms were assessed by questionnaire and included wheeze (Has your chest ever made a wheezing or whistling sound, if yes in the last 12 months?), shortness of breath, (using a modification of the British Medical Research Council questionnaire 17 ), cough and sputum (Do you usually cough/bring up phlegm first thing in the morning/during the day or night/on most days for as much as 3 months each year?) and chest tightness (Have you ever felt tight in the chest, if yes in the last 12 months?).
Past medical history (presence or absence) of respiratory disease was assessed by asking respondents if they had ever been told by a doctor that they had asthma or bronchial asthma, bronchitis, hay fever/ allergic rhinitis, pneumonia, pleurisy or obstructive sleep apnoea (OSA). Co-morbidities were also assessed as follows: 'Have you ever been told by a doctor that you have….depression, diabetes, cancer, cardiovascular disease, back pain?'. Smoking habits (never, former or current smokers (<15/day and >15/day)), levels of usual physical activity (International Physical Activity Questionnaire (IPAQ) short form questionnaire 18 ) and current medications (including vitamin supplements) were also recorded.
Height was measured using a stadiometer and weight was measured with participants in light clothes and body mass index (BMI, kg/m 2 ) was then calculated. Spirometry was assessed using an Easyone (Model 2001) (NDD Medical, Zurich, Switzerland) and EasyWare PC software (Version 2.14.4.0, Berlin, MA, USA) according to the American Thoracic Society standards 19, 20 and performed by research assistants trained in spirometry at the Thoracic Society of Australia and New Zealand-accredited training course. Postbronchodilator values were used for this analysis. Participants were defined to have COPD if forced expiratory volume in 1 s/forced vital capacity (FEV 1 /FVC) ratio was <0.7 and FEV 1 % predicted <80%.
Sleep apnoea screening devices (ApneaLink dual channel devices from Resmed, Sydney, Australia) were randomly offered to participants to use over one night at home (about 50% had an overnight sleep study) and, for these participants the apnoea-hypopnoea index (AHI) was calculated and participants were defined to have OSA if AHI > 19.
Serum 25-hydroxyvitamin D (25OHD) was measured by immunoassay on Abbott ARCHITECT platform (Abbott Laboratories, Abbott Park, IL, USA); 117 samples (randomly selected within 3 strata of 25OHD) were also assayed using isotope dilution liquid chromatography/tandem mass spectrometry (LC-MS/MS) according to published methods, 21 with a strong correlation between the two techniques (r = 0.94).
Statistical analysis
Descriptive statistics are presented as mean (SD) for quantitative variables and percent for categorical variables. Logistic regression models (for binary respiratory outcome variables) and linear regression models (for quantitative respiratory outcome variables) were used to assess the association of vitamin D level with respiratory outcomes after adjustment for potential confounders. Vitamin D was assessed as a categorical variable (25OHD <50, 50-100 and >100 nmol/L) with 25OHD < 50 nmol/L signifying 'deficiency'. Results from logistic regression ( Table 2 ) are presented as estimated odds ratios (95% CI) with vitamin D 50-100 nmol/L as the referent level. Results from linear regression (Table 3) are presented as estimated coefficients (95% CI) representing the difference in mean respiratory outcome across vitamin D subgroups with vitamin D 50-100 nmol/L as the referent level. An extended model C with interaction terms was used to test whether the association between 25OHD and respiratory outcome was different across smoking groups, different for males and females and different for those taking and not taking vitamin D supplements.
RESULTS
In the full sample, the age range was 45-69 years, 45% were males, 10% were current smokers and 12% were taking vitamin D supplementation (Table 1) . Overall, mean vitamin D level was 81 nmol/L (SD: 26), 8% had vitamin D level <50 nmol/L, 73% had level 50-100 nmol/L and 19% level >100 nmol/L. The characteristics of the subset with spirometry were very similar to the full sample ( Table 1 ). The prevalence of vitamin D < 50 nmol/L (Fig. 1 ) was higher in females than in males for people not taking a vitamin D supplement. Mean level and prevalence of vitamin D < 50 nmol/L were similar for males and females taking a vitamin D supplement.
In the minimally adjusted model (Model A, adjusting for age, sex, season and smoking), a low level of vitamin D was significantly associated with asthma, bronchitis, OSA, wheeze, dyspnoea and chest tightness ( Table 2 ). The associations with asthma, bronchitis, wheeze and chest tightness remained statistically significant after further adjustment for BMI and level of physical activity (Model B) and chronic diseases (Model C). Analysis of the spirometry data showed that a low level of vitamin D (<50 nmol/L) was associated with significantly lower FVC in the minimally adjusted Model A, but the association was attenuated and nonsignificant in Models B and C (Table 3 ). A higher vitamin D level (>100 nmol/L) was associated with significantly higher FEV 1 and FVC and lower FEV 1 /FVC in Model A, but only the association with higher FVC remained significant after further covariate adjustment in Models B and C. The mean FVC (expressed as % predicted) was 1.17% higher in those with a vitamin D level >100 nmol/L as compared to those with vitamin D level 50-100 nmol/L (Model C; Table 3 ).
None of the tests for interactions were significant (all P > 0.05), indicating that associations between vitamin D and respiratory symptoms were similar across smoking groups, similar for males and females, and similar for participants taking and not taking vitamin D supplementation.
DISCUSSION
There is increasing interest in the role of vitamin D in chronic disease and clarification has been sought via epidemiological, genetic and intervention studies. [1] [2] [3] The current study aimed to assess the relationships between vitamin D level and respiratory symptoms, illness and lung function in a well-characterized Caucasian adult population. The prevalence of low serum vitamin D (<50 nmol
Evidence suggests that vitamin D is a factor associated with various chronic lung diseases namely asthma, COPD, interstitial lung diseases and cystic fibrosis as well as respiratory infections. 2, 23, 24 Opinion is divided as to whether vitamin D deficiency contributes to aetiology or is a manifestation of existing lung disease and/or its treatment.
Vitamin D has a number of potential aetiological links with respiratory health including its role in foetal lung development and effects on normal immune functioning. [25] [26] [27] Although previous data have not demonstrated a definitive answer with regard to causation of respiratory disease, two recent meta-analyses of vitamin D and asthma provide compelling evidence of an aetiological relationship. 5, 8 Respiratory symptoms were assessed separately in this study and the demonstration of increased symptoms of wheeze and chest tightness in those with low vitamin D levels could well signify the presence of either respiratory infection or asthma. Reported asthma was also significantly associated with low vitamin D levels. This finding is reinforced by the results of a recent meta-analysis of intervention studies that report that vitamin D administration reduces the risk of severe asthma and healthcare use in both adults and children. 8 The demonstration of increased risk of reported bronchitis with low vitamin D levels in this study could reflect increased rates of respiratory infection, as supported by the published literature. 28, 29 This study has shown that higher serum vitamin D levels are associated with a statistically significantly higher FVC but not FEV 1 . Black and Scragg 30 previously demonstrated that lower serum vitamin D levels are associated with a lower FEV 1 in a dose-dependent manner in a general population. Although this was not confirmed in the current study, the demonstration of a relationship between vitamin D and FVC corroborates the theory that vitamin D may impact lung function.
OSA is reported to be associated with vitamin D deficiency and there appears to be an inverse relationship between vitamin D and AHI. 31, 32 There are however a number of confounding factors that could influence this association. The current study has shown that an association exists but is no longer statistically significant following adjustment for BMI, physical activity and chronic disease.
The prevalence of vitamin D deficiency is increasing worldwide and along with this is the recognition of the role that vitamin D plays not only in bone health but also in extra-skeletal health. 33 The pathways of vitamin D production are complex and there are a number of confounding factors that impact vitamin D levels which necessitates adjustment in any relationship analysis. The three adjustment models in the current study account for both internal and external determinants of vitamin D levels. The adjustment for sex is clearly relevant for this study, which demonstrates that mean vitamin D level was higher in males than in females and that the prevalence of vitamin D deficiency was highest in females who were not taking a vitamin D supplements. Vitamin D supplementation did not significantly affect the relationship between serum 25OHD and respiratory outcomes. Physical activity levels are known to be linked to sun exposure and chronic disease severity. This is adjusted for in Model B along with BMI, a marker of obesity, as obesity can lower the circulating levels of vitamin D due to sequestration in adipose tissue and volumetric dilution. 34 The final adjustment for chronic disease in Model C accounts for a number of confounding factors. 1 Vitamin D receptor (VDR) genetics is one internal factor that this and many other studies are unable to address. Polymorphisms in the VDR gene have been associated with lower respiratory tract infections, viral bronchiolitis and COPD, 35, 36 and this may be due to a VDR association with innate immunity. 37 Investigating the role of VDR and adjustment for this factor is beyond the scope of this study.
Limitations of the present study include the crosssectional design which means causality cannot be inferred. As discussed, the study was unable to adjust for VDR genetics, nor could it address the effect of diet or the fact that UV exposure likely has on immune function independent of vitamin D. 38 However, the adjustment for a large number of potentially strong confounders and the moderately large representative community sample size are definite strengths of the study. This enables greater confidence in the validity of the findings of an increased risk of respiratory disease in adults with lower vitamin D levels.
In conclusion, respiratory illness and symptoms are associated with lower vitamin D levels in a relatively large representative adult Caucasian population. Lower vitamin D levels confer an increased risk of reported asthma, bronchitis and symptoms of wheeze and chest tightness after adjustment for potential confounders that include BMI, physical activity and chronic disease. Higher vitamin D serum levels correlate with higher levels of lung function. The findings in this study coupled with recent studies investigating asthma outcomes and use of vitamin D supplements 5, 8 strengthen the proposed mechanistic relationship between vitamin D deficiency and respiratory disease. 
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